Figure 2.

Antihyperalgesic effect of repeated administration of PC1. Repeated systemic injections of PC1 (150 µg kg⁻¹, twice a day) from day 3 to 9 after CCI abolished the CCI-induced thermal hyperalgesia for about 2 weeks (A) and prevented the later development of tactile allodynia (B). Repeated administration of PC1 (150 µg kg⁻¹ s.c. twice a day) from day 17 to 20 significantly reduced but did not abolish thermal (C) and tactile (D) hyperalgesia which slowly reappeared after treatment withdrawal. Data represent means ± SEM of six to nine mice. °P < 0.05; °°P < 0.01; °°°P < 0.001 CCI/PC1 versus CCI/saline mice; two-way anova, followed by Bonferroni's test.